Biogen (BIIB) PT Lowered to $290 at Needham & Company
Tweet Send to a Friend
Needham & Company analyst Ami Fadia lowered the price target on Biogen (NASDAQ: BIIB) to $290.00 (from $292.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
